Molycop integration begins—watch the one-off costs and deleveraging credibility
Tega's transformational $1.5B Molycop acquisition closes June 1. Q1 FY27 will show the first month of consolidation, ~$30M in integration costs, and critically—management's path to sub-2.5x leverage within four years.
The Setup: One Month of Molycop, Heavy Integration Costs
Tega Industries completed its $1.5 billion acquisition of Molycop (a global grinding media leader for mining) on June 1, 2026. For Q1 FY-2027 (ended June 30), consolidated results will capture exactly one month of Molycop operations—from June 1 through month-end. This is a historic moment for Tega: the acquisition transforms it from a ₹8,950 Cr standalone miner into a bundled mining services powerhouse with 24 manufacturing sites globally. However, the print will be clouded by two material headwinds. First, ~$30 million in one-off transaction and refinancing costs will depress reported PAT. Second, consolidated leverage will spike: Molycop's existing $1 billion debt (now refinanced to $780M at lower cost) plus INR 1,500 Cr facility at Tega parent will land the combined entity at an estimated 4.0–4.5x Debt/EBITDA—a material jump from Tega's pre-acquisition ~0.3x. The critical read will be management's credibility on deleveraging: do they have a believable roadmap to sub-2.5x within four years?
~₹200–250 Cr
One month (June) only; full-quarter impact flows from Q2 onwards. Watch for exit run-rate color.
~₹250 Cr (~$30M)
Transaction, refinancing, separation, and integration charges. Expect management to itemize clearly.
~4.0–4.5x
Peak leverage in FY27 due to full-year Molycop debt plus refinancing. Path to 3.0–3.5x by FY28 critical to validate.
~3% YoY
Downgraded due to deferred mine restarts globally. Monitor for any further cuts or optimism on recovery timelines.
What a strong Q1 would look like: Molycop's one month contributes ₹200+ Cr in revenue, with EBITDA margins in line with expectations (~30%+). Management breaks out one-off costs transparently and reiterates FY27 pro-forma guidance with confidence. Critically, they articulate a clear deleveraging roadmap—asset sales timelines, EBITDA growth assumptions, and refinancing plans—that credibly gets to 3.5x by FY28 and sub-2.5x by FY30. Management also confirms customer wins and early synergy capture (bundled orders, cost eliminations). What a weak Q1 would look like: Molycop's contribution is lighter than expected, signaling integration or operational friction. One-off costs balloon beyond $30M or remain vague. Management provides no pro-forma guidance or fuzzy deleveraging targets ('we are focused on cash generation'), raising concerns about commitment to debt reduction. EBITDA margins compress or integration headwinds emerge. Leverage stays >4.5x with no credible path down, and FII selling resumes.
On Track? The Deleveraging & Integration Thesis
Tega's pre-acquisition FY26 revenue was ₹8,950.96 Cr. Standalone, the company has demonstrated steady mining services demand, but the TAM was historically capped at a regional player scale. Molycop—with $1.5B enterprise value and a global grinding media footprint—expands this universe dramatically. The strategic logic is sound: combine Tega's specialized mill liner technology with Molycop's scale, product breadth, and customer base to create a one-stop mining services shop. However, execution risk is material. The acquisition occurs in a weak global mining cycle (Molycop's own FY27 growth guidance is just 3%, down from prior expectations due to delayed mine restarts). CRISIL has downgraded Tega's credit rating post-acquisition due to elevated leverage, signaling the rating agencies' concern about near-term debt serviceability. The acid test for Q1 results: does management demonstrate that (a) Molycop is integrating smoothly, (b) synergies are materializing, and (c) a realistic multi-year deleveraging pathway exists? If management is vague or overly optimistic about growth offsetting debt burden, the market will punish the stock.
Since Last Quarter: Material Events & Filings
1 · Molycop Acquisition Close (June 1)
Deal completion with Apollo Funds consortium as co-investor. Molycop's existing $1B debt refinanced to $780M at lower cost (8.1–8.2%). INR 1,500 Cr facility drawn at Tega parent. First consolidated month appears in Q1 FY27 results. One-off costs of ~$30M (transaction, refinancing, separation) to impact Q1 PAT.
2 · New CFO Appointed (August 6)
Mr. Ravi Narayan Joshi (Chartered Accountant) appointed as CFO and KMP, effective immediately, replacing interim CFO (Ganguly) post-Khaitan resignation in April. First earnings call with new CFO; expect articulation of deleveraging strategy and capital allocation priorities.
3 · CRISIL Rating Downgrade
CRISIL downgraded Tega Industries' credit rating following the Molycop acquisition announcement due to elevated leverage and debt serviceability concerns. This signals rating agencies' caution on the debt burden; equity investors will watch for deleveraging credibility.
4 · Chile Subsidiary Tax Appeal Dismissed (July 15)
Tega Chile SpA's tax loss appeal upheld unfavorably. INR 8.73 Cr exposure on the books. Subsidiary issue; monitor for provision adjustments in Q1 results. Routine but noted.
5 · Australia Subsidiary De-registered (June 4)
Wholly-owned Tega Industries Australia Pty Ltd successfully de-registered. Clean exit from unprofitable jurisdiction; immaterial P&L impact.
6 · FY26 Final Dividend Approved (May 29)
Board approved ₹2 per share (20%) final dividend for FY26. Payout despite acquisition signals confidence in cash generation and shareholder returns; capital structure still allows dividends post-Molycop close.
What to Watch on August 13
1 · Molycop's June revenue, EBITDA, and margins
Expect a one-page breakdown of Molycop's Q1 contribution (June only). Watch for revenue, EBITDA, and margin %—are they in line with pre-acquisition expectations or showing integration friction? Exit run-rate (June actuals) will inform FY27 guidance.
2 · One-off costs—transparent itemization
The ~$30M charge must be clearly broken down: transaction costs, refinancing charges, separation costs, integration expenses. Vague or lumpy presentation raises red flags on hidden liabilities.
3 · FY27 pro-forma guidance & leverage roadmap
This is the acid test. Does management provide FY27 pro-forma guidance (combined revenue, EBITDA, PAT)? Do they articulate a credible multi-year deleveraging pathway—Debt/EBITDA targets, timing to sub-2.5x, and the sources (cash flow, asset sales, equity raises)? Vague guidance = re-rating risk.
4 · Consolidated leverage metrics & covenant headroom
Investors will scrutinize net debt/EBITDA (consolidated post-Molycop), interest coverage, and any covenant amendments. Tight headroom or refinancing risk = negative. Monitor debt maturity profile—are there near-term refinancing hurdles?
5 · Synergy realization & order book updates
Early wins matter: customer wins, bundled orders, cost synergies identified. Order book color (Tega + Molycop combined) and customer pipeline will indicate integration velocity and confidence in FY27 growth.
6 · Mine restart timelines & Molycop demand outlook
Given 3% FY27 growth guidance, management's color on global mining recovery, deferred mine restart timelines, and customer commentary will be critical. Any reduction in growth expectations = negative; any upside = re-rating catalyst.
Tega's Q1 FY27 is a pivotal quarter—the first official consolidation of a transformational acquisition that redefines the company's scale and ambition. The Street is cautiously constructive (₹1,930–₹2,084 target), but execution is uncertain. One-off costs will suppress reported earnings, leverage will spike to 4.0–4.5x (triggering CRISIL's downgrade), and global mining remains weak. The result will be overshadowed by one question: does management credibly demonstrate that Molycop is integrating well, synergies are real, and a pathway to sub-2.5x leverage within four years is achievable? If yes, the ₹2,000+ target is justified. If no—if guidance is vague, deleveraging timelines slip, or integration friction emerges—equity investors will take this as a warning signal. Watch the pro-forma guidance, the one-off cost itemization, and especially the deleveraging roadmap. That trifecta will set the next 12 months of valuation momentum.
Acquisition-driven scale masks operational loss
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Legacy Tega EBITDA margins (22.1% vs 19.1% prior) beat FY26 guidance of 22%. Consumables 15% CAGR maintained. But Molycop synergies and cross-sell deferred to Q3–Q4; volumes down YoY.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Consolidated revenue jumped 384% to ₹1,723 Cr on Molycop acquisition, but net loss of ₹108.3 Cr (NPM -6.2%) reflects ₹190 Cr one-time integration costs and ₹110–120 Cr annual finance charge. Legacy Tega consumables strong (21% growth, 22.1% margin), but equipment missed (-44%) and mining-cyclical positioning leaves debt burden a risk if market softens.
₹1723.4 Cr
Revenue · +384% YoY₹-108.3 Cr
Reported PAT · −406.4% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Strong quarterly performance with margin expansion
OVERSTATEDOperational EBITDA solid (15% adj. margin) but net loss ₹108.3 Cr (NPM -6.2%) due to ₹190 Cr one-time costs
Legacy Tega EBITDA margins improved to 22.1% from 19.1%
METLegacy Tega revenue ₹4.3 Cr (+21% YoY), EBITDA margin 22.1% confirmed; but represents only 25% of group revenue
Order book of ₹12.3 billion provides visibility
Partial₹12.3 Cr order book for Tega legacy; ₹9.6 Cr executable within 1 year; Molycop order book not disclosed
Molycop contributed ₹12.9 Cr revenue in one month
METMolycop ₹12.9 Cr revenue for June only (1 month of FY27); EBITDA ₹1.6 Cr (13% margin); margins 30% gross, but per-ton pricing tied to steel indices
Equipment revenue shortfall due to customer clearance delays
METEquipment revenue ₹0.36 Cr vs ₹0.64 Cr prior year (-44%); acknowledged as temporary; EBITDA breakeven
Earnings quality
What changed since the last call
Molycop integration expense backlog
DowngradeQ1 booked ₹190 Cr; Ankur Periwal asked if ₹75–80 Cr more expected; Mehul confirmed ₹190 Cr was it — but prior quarter had ₹70–80 Cr, so total acquisition drag ~₹265 Cr vs ₹110 Cr in initial guidance range.
Equity raised ₹50 Cr goodwill
NewIND-AS 103 provisional goodwill ₹49.96 Cr (USD 528M); write-down if Molycop EBITDA < ₹1.6 Cr/month sustained.
Debt deleveraged ₹32.18 Cr (USD 340M)
UpgradeNet debt fell from ₹95.8 Cr (March) to ₹63.66 Cr (June) via refinancing + equity; strengthens liquidity post-acquisition.
Cross-sell synergies delayed
DowngradeMehul said 'Q3–Q4 onwards', not immediate. Teams still 'getting together' — means momentum not yet reflected in FY27 guidance.
The Q&A
Analysts pressed hard on cross-sell numbers (Ankur), Molycop seasonality & margins (Ankur, Varun), debt & capex (Vikas, Varun), equipment miss, and Chinese competition (Varun, Lance). Management held firm on 15% consumables CAGR, acknowledged equipment delays as temporary, and defended Molycop's pricing model (per-ton margin protection via steel indices). No major concessions; tone remained confident but cautious on timing.
Cross-sell revenue ramp — Ankur Periwal, Axis Capital
DodgedRevenue ramp expected Q3–Q4 onwards. Teams being strategized; markets identified where Tega strong and Molycop can leverage, and vice versa. Request couple quarters patience; will provide definitive guidance later.
Molycop margin sustainability — Ankur Periwal, Axis Capital
AnsweredMargin should be relatively flat. Molycop focuses on per-ton profit, not % of sales, because ~85% of contracts tied to steel indices. This protects gross margin from price volatility.
Chile plant commissioning — Ankur Periwal, Axis Capital
AnsweredSoft commissioning Jan 2027, commercial production March 2027, subject to regulatory approvals. Two-month window for clearances post-construction.
One-time cost finality — Ankur Periwal, Axis Capital
AnsweredThis is it. We've factored everything into Q1 results.
Total debt positions — Vikas Gupta, Wealth Guardian
AnsweredTega group: ₹112 Cr (includes ₹26 Cr redeemable preference shares). Molycop: USD 672 million net debt (₹63.66 Cr).
Capex expectations — Vikas Gupta, Wealth Guardian
AnsweredMolycop: USD 28 million for this 10-month period; normalized ~USD 30M annually; next 2 years low–mid USD 30M depending on expansion.
Molycop pricing & volume — Varun Jain, Dolat Capital
Answered~85% of contracts tied to steel indices; revenue moves up/down with steel. Internally focus on per-ton margin (constant basis). Revenue per ton volatile, profit per ton protected.
Molycop volume trend — Varun Jain, Dolat Capital
Partial12-month volume ended June 2026: 1.204M tons (vs 1.223M prior year, -1.6% YoY). Expected growth 5% volumes, 4% EBITDA on 10-month basis. Early in acquisition; formal guidance later.
Finance cost & debt for FY27 — Varun Jain, Dolat Capital
AnsweredFinance cost ₹110–120 Cr for full year. Debt primarily ABL, fluctuates with bar payment timing; anticipated decline by year-end.
Molycop market share & regional exposure — Chirag, Centrum Broking
Partial>50% market share in core regions. South America largest (copper); North America major gold/copper; Australasia strong; Africa growing (Tega strength benefit).
Consumables growth & margin — Chirag, Centrum Broking
PartialMaintaining 15% CAGR on consumables. Cross-sell accretive but timing uncertain (couple quarters to finalize). EBITDA margin 20–23% annually sustainable; able to pass through commodity cost inflation.
Freight cost inflation — Rushabh Doshi, Nirmiti Advisors
AnsweredTega: container prices up; passed through to customers (~1 quarter lag). Molycop: hedges freight rates; no direct P&L impact.
Non-core asset sales — Rushabh Doshi, Nirmiti Advisors
PartialIdentifying non-productive land parcels; evaluating opportunities. Will use proceeds for debt paydown. No material impact to Molycop EBITDA.
FX risk exposure — Rushabh Doshi, Nirmiti Advisors
AnsweredMolycop: USD-denominated; Spain & Australia exceptions. Formal hedging program for FX exposure; hedge immediately for non-USD contracts; historically no material FX impact to EBITDA.
Consumables guidance mismatch — Nishita, Sapphire Capital
AnsweredNo seasonality. Q4 orders serviced in Q1, so not comparable. Long-term sustainable guidance 15% CAGR.
Consolidated margin outlook — Nishita, Sapphire Capital
AnsweredYes, expect consolidated EBITDA margin in 15% range for full year.
Guidance
Consumables 15% long-term CAGR
HighReaffirmed; Q1 +36% YoY skewed by Q4 order pull-forward, but sustainable CAGR target maintained.
Molycop 5% volume growth (10-month period FY27)
MediumEarly in integration; formal long-term guidance deferred to later quarters. Cross-sell upside not yet quantified.
Consolidated EBITDA margin ~15% full year
HighQ1 achieved 15% (₹260 Cr / ₹1,723 Cr); expected to stay in range pending integration progress.
Consumables EBITDA margin 20–23% annually
HighQ1 delivered 24.1%; able to pass through commodity cost inflation with ~1 quarter lag.
FY27 total capex ~USD 68 million (₹540 Cr approx)
HighTega excl. Molycop USD 40M (incl. Chile plant); Molycop USD 28M (10-month estimate).
Risks the call surfaced
Equipment business execution
MediumEquipment revenue fell 44% to ₹36 Cr due to customer clearance delays; EBITDA breakeven. Management confident long-term but near-term weakness evident.
Molycop integration execution
MediumOnly 1-month consolidated (June); volumes down 1.6% YoY (1.204M vs 1.223M tons). USD 20M synergies over 2–2.5 years is modest. Cross-sell deferred Q3–Q4.
Goodwill impairment
High₹50 Cr (USD 528M) provisional goodwill recorded per IND-AS 103; subject to finalization within 1 year. Write-down risk if Molycop EBITDA deteriorates below current run rate.
Finance cost burden
MediumFY27 finance cost ₹110–120 Cr annualized (vs ₹260 Cr adjusted EBITDA). Even without one-time costs, net profit limited. Debt ₹63.66 Cr (USD 672.5M) still material post-deleveraging.
Commodity & competitive pressure
MediumVarun Jain flagged Chinese competition in grinding media in Latin America. Lance defended on product quality & service, but risk acknowledged in core region.
Management
Score 6/10. Transparent on breakdown (Tega legacy 21% growth, Molycop 1-month 13% margin). Heavy use of 'adjusted EBITDA' rhetoric, but acknowledged one-time costs. Separate reporting helps clarity but NDA-shielded on customer names. Tega legacy beat margin guidance (22.1% vs 22% FY26). Consumables 15% CAGR maintained. Molycop EBITDA +11% YoY via cost control (volumes down 1.6%). But cross-sell deferred Q3–Q4; equipment -44% unpredicted.
1 · Q3/Q4 FY27
Molycop cross-sell revenue ramp (delayed pending team alignment)
2 · Jan 2027
Chile plant soft commissioning; March commercial production
3 · Next 2–2.5 years
USD 20 million synergies realization via SG&A, procurement, operational efficiency
Legacy Tega consumables strong (21% growth, 22.1% margin), but equipment missed (-44%) and mining-cyclical positioning leaves debt burden a risk if market softens.
Tega swings to ₹86 Cr consolidated loss in Q1FY27 on one-off Molycop deal costs
PAT -406.4% YoY · revenue +384% · margins compressing · miss vs street
₹1,723.44 Cr
+384% YoY
₹-108.25 Cr
-406.4% YoY
-6.22%
-15.7pp YoY
₹-11.47
Tega Industries' consolidated Q1 FY27 print — the first quarter to include Molycop Group, acquired for $1.5 billion and consolidated from 1 June 2026 — swung to a loss of ₹86.19 Cr attributable to owners (₹108.25 Cr including minority interest of ₹22.06 Cr), against profits of ₹35.34 Cr a year ago and ₹42.67 Cr last quarter. Consolidated EPS was -₹11.47 versus +₹5.31 YoY and +₹5.68 QoQ. Revenue jumped to ₹1,723.44 Cr (+384% YoY, +227% QoQ), but this is almost entirely inorganic: Molycop's newly created Grinding Media segment contributed ₹1,291.64 Cr in its first, partial month of consolidation, while the pre-existing Consumables-Others business grew a more modest ₹294 Cr to ₹397.18 Cr YoY and Equipments fell to ₹35.78 Cr from ₹64.32 Cr.
Q1 FY-2027 vs prior quarters
The loss traces to a known, flagged transition cost rather than operating weakness. Other expenses carried a one-time ₹190.96 Cr Molycop acquisition/advisory charge, finance costs jumped to ₹116.71 Cr from ₹5.09 Cr QoQ on roughly $838 million of new acquisition debt, and depreciation/amortisation rose to ₹73.62 Cr from ₹25.22 Cr QoQ as newly recognised intangibles (₹3,429.53 Cr, provisional) began amortising. Reported EBITDA margin collapsed to ~4.2% of total income from 15.6% YoY / 11.4% QoQ, but stripping out just the ₹190.96 Cr one-off, PBT would have been a profit of ~₹74.48 Cr and adjusted EBITDA margin ~15.2% — in line with the recent range. On that basis, adjusted PAT works out to roughly +134% YoY versus -406% reported, though even the adjusted number reflects one stub month of a newly added, much larger business rather than organic growth, so it isn't a like-for-like comparison. The standalone (pre-Molycop) business itself stayed healthy and largely insulated from deal costs, with PAT of ₹45.42 Cr, +18.3% YoY and +11.2% QoQ, and EPS of ₹6.05.
The stock went into the print at ₹1,545.7, down 5% over the past month of trading.
For context: revenue is at a 6-quarter high.
Management provided guidance for a 5% year-on-year revenue growth in FY26, with an adjusted EBITDA margin of 22%. The company expects continued strong performance in the equipment business (25% growth) and mid-to-high single-digit growth for consumables, targeting a 15%+ long-term CAGR for consumables. For FY27, Tega e
A Univest preview ahead of results had pegged Q1 revenue (ex-Molycop) at ₹359-413 Cr and PAT at ₹16-20 Cr, and had itself flagged roughly $30 million of one-off transaction/refinancing costs — directionally consistent with the ₹190.96 Cr charge actually booked, though the resulting swing to a loss is still a clear miss against that PAT estimate. Core (ex-Molycop) revenue of about ₹431.78 Cr came in at or just above the top of the street's ex-Molycop range. Management's FY27 guidance from the last concall (15% growth ex-Molycop, 3% for Molycop, 22% adjusted EBITDA margin, ~$55 million capex) cannot be fairly judged off one deal-cost-distorted, partial-consolidation quarter — this print is too early and too noisy to call a beat, miss, or in-line against that full-year target. The quarter's other developments — Tega Chile's tax loss appeal being dismissed (₹8.73 Cr exposure) and the appointment of Ravi Narayan Joshi as CFO on 6 August, just ahead of results — are minor relative to the Molycop integration and were not separately called out in the results themselves.
W1
Full three-month Molycop consolidation in Q2 FY27 — watch whether adjusted EBITDA margin holds near ~15% (Molycop itself guided at ~12% margin, 3% growth) and whether the ₹190.96 Cr transaction cost fully tapers off.
W2
Finance cost run-rate of ₹116.71 Cr this quarter against management's target to bring Molycop's leverage down to 3x within 3-4 years.
W3
Chile plant commissioning guided for early Q3 with revenue booking by Q4/next year (subject to regulatory approvals), and resolution of Tega Chile's ₹8.73 Cr tax exposure after its loss-carry-forward appeal was dismissed.
₹260 crore of solid EBITDA hides the ₹108 crore path to profitability
Revenue exploded 384% to ₹1,723 crore on Molycop acquisition, but net loss of ₹108.3 crore reflects ₹190 crore in one-time integration costs and ₹110–120 crore annualized finance charge. Underneath, adjusted EBITDA of ₹260 crore (15% margin) is solid—legacy Tega beat margin guidance—and the real story is whether Molycop cross-sell synergies materialize in Q3–Q4.
₹1,723 Cr
+384% YoY; Molycop ₹1,290 Cr (1 month)
-₹108.3 Cr
NPM -6.2%; significant swing from prior-year profit
₹260 Cr
15% margin; solid underlying operations
The headline tells one story—revenue exploded on the Molycop acquisition (effective 1 June). But the profit line tells another. A net loss of ₹108.3 crore looks catastrophic on the surface. Underneath lie two separate realities: ₹190 crore in one-time acquisition and integration costs booked in Q1, and an annualized finance burden of ₹110–120 crore from servicing the acquisition debt. Peel both away, and adjusted EBITDA of ₹260 crore (15% margin) is solid. Legacy Tega's consumables business beat margin guidance. The quarter is not a collapse; it is a transition.
Where the net loss came from
Net loss of ₹108.3 crore breaks down as: adjusted EBITDA ₹260 crore, minus ₹190 crore in one-time acquisition and integration costs, minus an estimated ₹110–120 crore annualized finance charge (pro-rated to Q1 ≈ ₹27–30 crore), minus tax and depreciation. The ₹190 crore is not a quarterly run-rate cost. Management confirmed on the call this was the catch-all for Q1 integration. However, disclosure of a prior-quarter estimate of ₹70–80 crore, plus this quarter's ₹190 crore, signals total acquisition drag of roughly ₹265 crore across FY-2027—well above initial guidance of ₹110 crore.
Strong quarterly performance with margin expansion
Adjusted EBITDA solid (15%), but net loss ₹108.3 Cr due to ₹190 Cr one-time costs + finance burden
Supported operationally; profit distorted by one-time
Legacy Tega EBITDA margins improved to 22.1% from 19.1%
Legacy Tega ₹435 Cr revenue (+23% YoY); EBITDA margin 22.1%; consumables ₹400 Cr (+36%), margin 24.1%
Fully supported; beat FY26 guidance (22%)
Molycop contributed ₹1,290 Cr revenue in June (1 month)
Molycop June-only revenue ₹1,290 Cr, EBITDA ₹160 Cr (13% margin); 12-month volume -1.6% YoY
Supported; volume contraction masked
Equipment shortfall due to customer clearance delays
Equipment ₹36 Cr vs ₹64 Cr prior year (-44%); EBITDA breakeven; acknowledged temporary
Supported; reversal timing unclear
Order book ₹12.3 Cr provides 1-year visibility
Legacy Tega order book ₹12.3 Cr, ₹9.6 Cr executable within 1 year; Molycop order book not disclosed
Partial; Molycop opaque
What changed on this call
Three material moves: (1) Goodwill of ₹50 crore (USD 528 million, provisional) on Molycop, subject to finalization within 1 year per IND-AS 103—a write-down risk if Molycop EBITDA slips below ₹1.6 crore/month. (2) Net debt deleveraged ₹32.18 crore (USD 340 million) this quarter via refinancing and equity support, reducing leverage post-acquisition. (3) Cross-sell synergies deferred to Q3–Q4 onwards ('request couple quarters patience,' per MD); teams still 'getting together' on strategy, meaning momentum is not yet reflected in FY-2027 guidance.
How the street is reading it: The stock rose +2.05% on day 1 and +3.86% by day 3 post-announcement, confirming the market initially valued acquisition upside over the reported loss. However, RSI now sits at 85.7 (overbought), and the stock trades 14.33% off its all-time high despite holding above 20-day and 50-day moving averages. Foreign institutional investors hold steady at 2.80% (up 0.66pp QoQ), while domestic institutions dipped to 18.68% (down 0.28pp). Promoters unmoved at 67.50%. The tape says the market has priced in acquisition hope, but momentum is showing fatigue.
Molycop >50% regional market share in grinding media; monthly EBITDA ₹160 Cr run-rate
Legacy Tega beat FY-2026 EBITDA margin guidance (22.1% vs 22% target)
Consumables +36% YoY, 24.1% EBITDA margin; 15% CAGR reaffirmed
Mining cycle tailwind: copper +4.8% CAGR, gold +2.2% CAGR; supply constraints favor pricing
Net debt reduced ₹32.18 Cr; liquidity strengthened post-refinancing
Reported net loss ₹108.3 Cr distorts underlying adjusted EBITDA ₹260 Cr (solid)
One-time integration costs ₹190 Cr in Q1; ₹75–80 Cr more expected (total ~₹265 Cr)
Molycop volumes down 1.6% YoY; pricing power capped by 85% steel-indexed contracts
Equipment revenue -44%, breakeven EBITDA; customer clearance delays lack reversal visibility
Cross-sell synergies deferred to Q3–Q4; teams still 'getting together' on strategy
Finance cost ₹110–120 Cr FY27 structural; offsets ~40% of adjusted EBITDA, limits net profit
Goodwill ₹50 Cr provisional; material write-down risk if Molycop EBITDA < ₹1.6 Cr/month
Goodwill impairment risk (₹50 Cr provisional)
HighIND-AS 103 goodwill subject to finalization within 1 year. Material write-down if Molycop EBITDA < ₹1.6 Cr/month sustained or synergy expectations unmet. Masks downside leverage.
One-time integration cost backlog (₹265 Cr total expected)
High₹190 Cr in Q1; ₹75–80 Cr more expected in FY-2026 close-out. Drag extends Q2–Q3, depresses near-term earnings visibility. Total drag ₹265 Cr vs ₹110 Cr initial guidance.
Net loss despite positive EBITDA (earnings quality)
High₹260 Cr adjusted EBITDA vs -₹108 Cr net profit. Gap widens from ₹190 Cr one-time + ₹110–120 Cr finance cost. Debt burden materially impairs equity profitability.
Molycop volumes down 1.6% YoY; pricing power hedged to steel indices
Medium12-month volume 1.204M tons (June) vs 1.223M tons prior year, despite 'ahead of expectations' talk. ~85% contracts steel-indexed limits margin expansion.
Equipment revenue collapsed 44%; reversal timing unclear
Medium₹36 Cr vs ₹64 Cr prior year. EBITDA breakeven. Customer clearance delays cited but no visibility on order conversion or Q2–Q3 ramp. Equipment miss impacts portfolio mix.
Cross-sell synergies deferred to Q3–Q4; execution unproven
MediumMehul said 'Q3–Q4 onwards,' not immediate. Teams 'getting together' to finalize markets and strategy. Deferred ramp = no tailwind in FY-2027 guidance; execution risk if timing slips.
Finance cost burden ₹110–120 Cr FY27 (structural)
MediumAnnualized finance cost offsets ~40% of adjusted EBITDA. Even without one-time costs, net profit limited. Debt USD 672.5 million material post-deleveraging.
Mining cycle cyclicality; copper/gold market softening scenario
MediumMolycop's per-ton margins depend on mining capex cycle and commodity volatility. No pricing power if capex cycle flips or Chinese competition intensifies in LatAm.
1 · Q3 or Q4 cross-sell revenue ramp
Management promised 'Q3–Q4 onwards' for cross-sell synergies. Watch for Molycop equipment penetration into Tega customer base and vice versa. If deferred past Q4 or fails to materialize, execution risk crystallizes and FY-2028 growth is at risk.
2 · Molycop EBITDA margin sustainability & volume recovery
June 1-month EBITDA ₹160 Cr (13% margin) is the baseline. Monitor whether volumes recover (currently -1.6% YoY) and whether steel-indexed pricing remains stable. If margin compresses below 12% or volumes decline further, goodwill impairment becomes probable.
3 · Chile plant commissioning (Jan soft, March commercial)
Management guided soft commissioning January 2027, commercial production March 2027, subject to regulatory approvals. Delays in commissioning are a downside risk. Successful ramp adds meaningful EBITDA capacity post-Q4 FY-2027; misses delay margin recovery.
4 · Net debt trajectory and refinancing headroom
Debt reduced ₹32.18 Cr this quarter, but USD 672.5 million remains material. Watch quarterly debt paydown and whether non-core asset sales proceed as planned. If mining cycle softens, refinancing risk and covenant tightness could limit capex flexibility.
5 · Equipment order conversion and legacy Tega margin durability
Equipment -44% needs to stabilize by Q2–Q3. Meanwhile, Tega consumables 24.1% EBITDA margin is the steady-state; ability to pass through commodity inflation via ~1-quarter lag is key to maintaining guidance.
Tega's Q1 is not a quarter-to-quarter blow; it is a pivot. Revenue exploded on acquisition; profit is depressed by one-time costs and a heavy finance burden that is structural, not temporary. Underneath, legacy Tega beat margin guidance and consumables momentum is real. This is an acquisition integration story, not an organic growth inflection. Returns from here depend on Molycop cross-sell synergies and Chile plant upside—both deferred to Q3–Q4 or later. Promoters hold firm at 67.50%, FII steady at 2.80%, but RSI at 85.7 signals the market has priced in hope. Hold for the next two quarters—cross-sell momentum in Q3–Q4 is the make-or-break catalyst.
The single number to track from here: whether Q3–Q4 consolidated EBITDA sustains the ₹260 crore run-rate (confirming Molycop cross-sell impact). If it does, synergies are real and goodwill is safe. If it stalls, impairment risk and downside repricing follow.